StockData

Kiniksa Pharmaceuticals International vs Liquidia

KNSA and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KNSA and LQDA compare

Kiniksa Pharmaceuticals International is the larger company, worth 2.9 times as much as Liquidia ($14.9B against $5.1B).

On earnings, Liquidia is cheaper: it trades at 40.8× trailing earnings, against 73.2× for Kiniksa Pharmaceuticals International.

Liquidia grew revenue faster over the last twelve months (2234% versus 58.2% for Kiniksa Pharmaceuticals International).

Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with 11.6% at Kiniksa Pharmaceuticals International.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 8 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKNSALQDA
Size and price
Market cap$14.9B$5.1B
Share price$95.11$56.73
Change, 1 year136%102%
Change, 5 years716%1280%
Beta (5Y)0.151.00
Employees366216
StockData Score
Total score14 (better)8
Valuation score00
Growth score4 (better)2
Performance score4 (better)3
Health score6 (better)3
Dividend score00
Valuation
P/E73.2×40.8× (better)
P/S15.8×11.3× (better)
P/B21.0× (better)26.0×
EV/EBITDA109×28.2× (better)
P/FCF75.8×33.7× (better)
FCF yield1.3%3.0% (better)
Fair value$16.72$32.46
Margin of safety−469%−74.8% (better)
Growth
Revenue growth (TTM)58.2%2234% (better)
Revenue growth, 5Y average–192%
Net income growth (TTM)205%–
EPS growth (TTM)189%–
Profitability
Gross margin90.2%–
Operating margin13.8%37.4% (better)
Net margin11.6%30.7% (better)
FCF margin20.8%33.4% (better)
Return on equity17.6%132% (better)
Return on invested capital60.2%–
Financial health
Debt / equity0.00–
Interest coverage–6.3×
Current ratio3.91 (better)2.31
Altman Z-score34.40 (better)10.49
Piotroski F-score8 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions29.9%81.1%
Held by insiders5.1%19.5%
Insider net buying, 12 months−$122M (better)−$227M
Short interest, % of float2.9%24.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.